NCT07647328
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Recruiting
PHASE3Ages 18+InterventionalTreatmentAstraZeneca
~150 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:CamizestrantRibociclib
At a glance
Recruiting sites
1 of 84 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of camizestrant and ribociclib by time to next treatment (TTNT)
Measured over Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment.
Conditions
Where it's being run
84 sites across 16 statesSpain18
South Korea16
France14
Germany8
Poland8
Italy5
Switzerland3
California2
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Efficacy of camizestrant and ribociclib by time to next treatment (TTNT)Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment.
TTNT is defined as time from the date of the first administration of study treatment to the earliest start date of subsequent anti-cancer medication or death. The primary measure of interest is the TTNT event-free rate at 2 years.